glp 1 and crohn's GLP-1 Agonists Disease: Risks and Management SAFETY AND CLINICAL EFFECTIVENESS OF
Description
Novo Nordisk was close behind, also generating nearly $12 billion, driven by massive demand for Ozempic and Wegovy
- A new marketing language is emerging with products being positioned as GLP-1 Friendly. Yes they are actually saying that now
These compounds have demonstrated promise as natural glp 1 agonists and may complement dietary and lifestyle strategies for enhanced outcomes
Cited in 37 publications
